We use cookies for a better user experience. Read our Privacy Policy

I Agree

AI in Drug Discovery Market Forecast Report, 2021-2031

AI in Drug Discovery Market (Offering: Software and Services; Application: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Metabolic Diseases, Cardiovascular Diseases, and Others; Technology: Machine Learning and Other Technologies; Drug Type: Small Molecules and Large Molecules; and End User: Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academics & Research, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Artificial Intelligence (AI) Help Find Novel Treatments for COVID-19 Patients

Quick drug identification for COVID-19 could serve as a boon, as many countries struggle to contain the deadly virus. Lockdowns and stringent restrictions on the movement of people have had a negative impact, including tremendous losses incurred by companies in the AI in drug discovery market. However, if proper treatment is found for treating COVID-19 patients, it could help in many ways. A University of Michigan research team has used an AI-powered image to identify over 17 existing drugs to reduce coronavirus infection in cells. Such methods and techniques help discover the efficacy of existing drugs against COVID-19, ultimately contributing to the growth of the AI in drug discovery market.

ai in drug discovery market infographic

Request a sample to get extensive insights into the AI in Drug Discovery Market

Rise in Incidence of Chronic Diseases Propels Need for AI in Drug Discovery

The incidence of chronic diseases is increasing at a rapid pace across the globe. According to the Centers for Disease Control and Prevention (CDC), six in 10 adults in the U.S. have a chronic disease, and four in 10 adults have two or more. Furthermore, the CDC also highlights that chronic diseases such as heart disease and diabetes are the leading causes of death in the U.S. Such statistics shed light on the growing prevalence of chronic diseases and the need to bring down the fatality rate caused due to these diseases.

AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases. Thus, these factors will led to considerable growth of the AI in drug discovery market during the forecast period of 2021-2031.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Profound Impact of Oncology on Market Growth

The role of AI in oncology is estimated to offer significant growth opportunities. AI can help the researchers understand how cancer cells become resistant to anticancer drugs, eventually leading to drug development and adjust drug use. AI technologies such as machine learning can act as a catalyst in existing anticancer drug research.

Paige’s, an AI diagnostic technology startup is a classic instance of the rising advancements in the oncology segment. The company uses machine learning to enable pathologists to facilitate precise cancer diagnoses through the images of tissue samples. Such developments are expected to fuel the growth of the AI in drug discovery market.

Popularity of Mindful AI to Offer Breakthrough Opportunities

Mindful AI is a fast emerging ideal solution for developing drugs in a more human-centric and responsible manner. Mindful AI is an intention-based approach used for creating effective AI-based technologies. With mindful AI, pharmaceutical companies can not only know about how quickly a drug can be developed but also about how inclusive it is in terms of effectiveness. Thus, the growing popularity of mindful AI in the pharmaceutical industry will present promising growth opportunities, thus driving the overall AI in drug discovery market.

Advancements in Treatment of Neurological Diseases to Open Profitable Avenues

The use of AI in treating neurological disorders could present an array of growth opportunities. Various players in the pharmaceutical industry are collaborating for exploring novel neurological diseases solutions. PharmEnable, the U.K.-based drug discovery company and Sosei, a Japan-based firm, are collaborating to use the Sosei Heprares CPCR-focused drug design platform and PharmEnable’s AI technologies to discover drug leads. Similar developments will assure extensive growth for the AI in drug discovery market.

ai in drug discovery market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on AI in Drug Discovery Market

Analysts’ viewpoint

The AI in drug discovery market is estimated to expand at a CAGR of 36.1% during the forecast period of 2021-2031. The global market is projected to cross US$ 10.93 Bn by 2031. The cases of chronic diseases, especially cardiovascular disorders and diabetes, are increasing at an accelerated rate, eventually boosting the need for AI in drug discovery platforms. Furthermore, the use of AI in treating neurological disorders will help in increasing the growth rate. Players in the AI in drug discovery market should focus on using Mindful AI to design and develop effective drug discovery platforms. Furthermore, advancements made by AI in findings related to COVID-19 are anticipated to witness substantial growth.

AI in Drug Discovery Market: Overview

  • Artificial intelligence (AI) has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as deep learning, machine learning, or artificial neural networks) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, increase productivity while simultaneously enhancing treatment and patient throughput.
  • Artificial intelligence in healthcare is booming, and with the limitless possibilities offered by this cutting-edge technology, a slew of business behemoths are investing in healthcare applications. Integration of AI and machine learning tools in drug discovery & development applications could enhance healthcare outcomes by increasing drug discovery efficiency, facilitating targeted molecule identification, minimizing drug discovery timeframes, and, most importantly, lowering drug development costs for drug manufacturers.
  • Moreover, various pharmaceutical firms and entrepreneurs across the world are launching projects and investing in the creation of AI and machine learning technologies for bettering drug discovery and improving drug development outcomes

AI in Drug Discovery: Market Drivers

  • Increase in cross-industry alliances and collaborations drives the global AI for drug discovery market. Rise in relevance of AI in drug discovery & development and surge in funding for R&D activities, including AI technology in the field of drug research, are projected to propel the global market.
    • In July 2020, IBM acquired WDG Automation to advance AI-Infused Automation Capabilities for Enterprises. This acquisition advances IBM's comprehensive AI-infused automation capabilities, spanning business processes to IT operations.
  • Artificial intelligence (AI) drug discovery company Exscientia expanded its ongoing anti-viral drugs partnership with the U.K.’s national synchrotron facility Diamond Light Source and the University of Oxford across the Atlantic Ocean to include California-based Scripps Research’s Calibr and focus on COVID-19 research.
    • In January 2021, Nucleai, the U.S.-based provider of biomarkers-based therapy, signed a collaboration agreement with Debiopharm Pharma Company, a pioneer in drug development. According to the terms of the agreement, Debiopharm Pharma Company will use Nucleai’s artificial intelligence (AI) platform for its pipeline oncology drug candidates.
  • Hence, increase in cross-industry collaborations and partnerships drives the global AI in drug development market

Market Segmentation: AI in Drug Discovery Market

  • In terms of drug type, the global AI in drug discovery market has been bifurcated into large molecules and small molecules
  • Based on application, the global AI in drug discovery market has been classified into oncology, infectious diseases, neurological disorders, rare diseases, metabolic diseases, cardiovascular diseases, and others
  • In terms of end user, the global AI in drug discovery market has been divided into pharmaceutical & biotechnology companies, contract research organizations, academics & research, and others
  • Based on offering, the global AI in drug discovery market has been split into software and services
  • In terms of technology, the global AI in drug discovery market has been segregated into machine learning and other technologies
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The AI in drug discovery market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: AI in Drug Discovery Market

  • In terms of region, the global AI in drug discovery market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America is projected to account for the largest share of the global AI for drug discovery market in the near future, as the region is technologically advanced and one of the early adopters of latest technologies. High awareness about AI in drug discovery among the key players in the region is another driver of the global AI for drug discovery market.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the global AI in drug discovery market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Major Players

  • The AI in drug discovery market report concludes with the company profiles section, which includes key information about major players in the global AI in drug discovery market
  • Leading players analyzed in the report include
    • Exscientia
    • GNS Healthcare
    • Cloud Pharmaceuticals, Inc.
    • Benevolent AI
    • PathAI, Inc.
    • Berg Health
    • Atomwise
    • Insitro
    • Cyclica
    • BlackThorn Therapeutics
    • Insilico Medicine
    • Notable Labs
    • Standigm
    • Recursion Pharmaceuticals
    • BioSymetrics
  • Each of these players has been profiled in the AI in drug discovery market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

AI in Drug Discovery Market – Segmentation

TMR’s study on the global AI in drug discovery market includes information divided into six segments: offering, technology, drug type, application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global AI in drug discovery market are discussed in detail.

Drug Type
  • Small Molecules
  • Large Molecules
Application
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Rare Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Others
Technology
  • Machine Learning
  • Other Technologies
Offering
  • Software
  • Services
End User
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academics & Research
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
AI in Drug Discovery Market Forecast Report, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of AI in drug discovery market?

AI in drug discovery market is projected to reach US$ 10.93 Bn By 2031

What is the anticipated CAGR of the AI in drug discovery market in the forecast period?

AI in drug discovery market is anticipated to expand at a CAGR of 36.1% during the forecast period

What are the key driving factors for the growth of the AI in drug discovery market?

AI in drug discovery market is driven by increase in pressure on drug manufacturers to reduce drug prices, rise in prevalence of lifestyle diseases and increase in healthcare expenditure

Which is the rising prominent segment in the AI in drug discovery market?

The machine learning segment held significant share of the AI in drug discovery market

Who are the key players in the global AI in drug discovery market?

Top Key players in AI in drug discovery market are Exscientia, GNS Healthcare, Cloud Pharmaceuticals, Inc., Benevolent AI, PathAI, Inc., BlackThorn Therapeutics, Insilico Medicine, Notable Labs, Standigm, Recursion Pharmaceuticals, and BioSymetrics

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global AI in Drug Discovery Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Introduction

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global AI in Drug Discovery Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.2. Technological Advancements

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid /long term impact)

6. Global AI in Drug Discovery Market Analysis and Forecast, by Offering

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Offering, 2017–2031

        6.3.1. Software

        6.3.2. Services

    6.4. Market Attractiveness Analysis, by Offering

7. Global AI in Drug Discovery Market Analysis and Forecast, by Technology

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Technology, 2017–2031

        7.3.1. Machine Learning

        7.3.2. Other Technologies

    7.4. Market Attractiveness Analysis, by Technology

8. Global AI in Drug Discovery Market Analysis and Forecast, by Drug Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Drug Type, 2017–2031

        8.3.1. Small Molecules

        8.3.2. Large Molecules

    8.4. Market Attractiveness Analysis, by Drug Type

9. Global AI in Drug Discovery Market Analysis and Forecast, by Application

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Application, 2017–2031

        9.3.1. Oncology

        9.3.2. Infectious Diseases

        9.3.3. Neurological Disorders

        9.3.4. Rare Diseases

        9.3.5. Metabolic Diseases

        9.3.6. Cardiovascular Diseases

        9.3.7. Others

    9.4. Market Attractiveness Analysis, by Application

10. Global AI in Drug Discovery Market Analysis and Forecast, by End-user

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Pharmaceutical & Biotechnology Companies

        10.3.2. Contract Research Organizations

        10.3.3. Academics & Research

        10.3.4. Others

    10.4. Market Attractiveness Analysis, by End-user

11. Global AI in Drug Discovery Market Analysis and Forecast, by Region

    11.1. Key Findings

    11.2. Market Value Forecast, by Region

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Market Attractiveness Analysis, by Country/Region

12. North America AI in Drug Discovery Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Offering, 2017–2031

        12.2.1. Software

        12.2.2. Services

    12.3. Market Value Forecast, by Technology, 2017–2031

        12.3.1. Machine Learning

        12.3.2. Other Technologies

    12.4. Market Value Forecast, by Drug Type, 2017–2031

        12.4.1. Small Molecules

        12.4.2. Large Molecules

    12.5. Market Value Forecast, by Application, 2017–2031

        12.5.1. Oncology

        12.5.2. Infectious Diseases

        12.5.3. Neurological Disorders

        12.5.4. Rare Diseases

        12.5.5. Metabolic Diseases

        12.5.6. Cardiovascular Diseases

        12.5.7. Others

    12.6. Market Value Forecast, by End-user, 2017–2031

        12.6.1. Pharmaceutical & Biotechnology Companies

        12.6.2. Contract Research Organizations

        12.6.3. Academics & Research

        12.6.4. Others

    12.7. Market Value Forecast, by Country, 2017–2031

        12.7.1. U.S.

        12.7.2. Canada

    12.8. Market Attractiveness Analysis

        12.8.1. By Offering

        12.8.2. By Technology

        12.8.3. By Drug Type

        12.8.4. By Application

        12.8.5. By End-user

        12.8.6. By Country

13. Europe AI in Drug Discovery Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Offering, 2017–2031

        13.2.1. Software

        13.2.2. Services

    13.3. Market Value Forecast, by Technology, 2017–2031

        13.3.1. Machine Learning

        13.3.2. Other Technologies

    13.4. Market Value Forecast, by Drug Type, 2017–2031

        13.4.1. Small Molecules

        13.4.2. Large Molecules

    13.5. Market Value Forecast, by Application, 2017–2031

        13.5.1. Oncology

        13.5.2. Infectious Diseases

        13.5.3. Neurological Disorders

        13.5.4. Rare Diseases

        13.5.5. Metabolic Diseases

        13.5.6. Cardiovascular Diseases

        13.5.7. Others

    13.6. Market Value Forecast, by End-user, 2017–2031

        13.6.1. Pharmaceutical & Biotechnology Companies

        13.6.2. Contract Research Organizations

        13.6.3. Academics & Research

        13.6.4. Others

    13.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Italy

        13.7.5. Spain

        13.7.6. Rest of Europe

    13.8. Market Attractiveness Analysis

        13.8.1. By Offering

        13.8.2. By Technology

        13.8.3. By Drug Type

        13.8.4. By Application

        13.8.5. By End-user

        13.8.6. By Country/Sub-region

14. Asia Pacific AI in Drug Discovery Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Offering, 2017–2031

        14.2.1. Software

        14.2.2. Services

    14.3. Market Value Forecast, by Technology, 2017–2031

        14.3.1. Machine Learning

        14.3.2. Other Technologies

    14.4. Market Value Forecast, by Drug Type, 2017–2031

        14.4.1. Small Molecules

        14.4.2. Large Molecules

    14.5. Market Value Forecast, by Application, 2017–2031

        14.5.1. Oncology

        14.5.2. Infectious Diseases

        14.5.3. Neurological Disorders

        14.5.4. Rare Diseases

        14.5.5. Metabolic Diseases

        14.5.6. Cardiovascular Diseases

        14.5.7. Others

    14.6. Market Value Forecast, by End-user, 2017–2031

        14.6.1. Pharmaceutical & Biotechnology Companies

        14.6.2. Contract Research Organizations

        14.6.3. Academics & Research

        14.6.4. Others

    14.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.7.1. Japan

        14.7.2. China

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Market Attractiveness Analysis

        14.8.1. By Offering

        14.8.2. By Technology

        14.8.3. By Drug Type

        14.8.4. By Application

        14.8.5. By End-user

        14.8.6. By Country/Sub-region

15. Latin America AI in Drug Discovery Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Offering, 2017–2031

        15.2.1. Software

        15.2.2. Services

    15.3. Market Value Forecast, by Technology, 2017–2031

        15.3.1. Machine Learning

        15.3.2. Other Technologies

    15.4. Market Value Forecast, by Drug Type, 2017–2031

        15.4.1. Small Molecules

        15.4.2. Large Molecules

    15.5. Market Value Forecast, by Application, 2017–2031

        15.5.1. Oncology

        15.5.2. Infectious Diseases

        15.5.3. Neurological Disorders

        15.5.4. Rare Diseases

        15.5.5. Metabolic Diseases

        15.5.6. Cardiovascular Diseases

        15.5.7. Others

    15.6. Market Value Forecast, by End-user, 2017–2031

        15.6.1. Pharmaceutical & Biotechnology Companies

        15.6.2. Contract Research Organizations

        15.6.3. Academics & Research

        15.6.4. Others

    15.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Market Attractiveness Analysis

        15.8.1. By Offering

        15.8.2. By Technology

        15.8.3. By Drug Type

        15.8.4. By Application

        15.8.5. By End-user

        15.8.6. By Country/Sub-region

16. Middle East & Africa AI in Drug Discovery Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Offering, 2017–2031

        16.2.1. Software

        16.2.2. Services

    16.3. Market Value Forecast, by Technology, 2017–2031

        16.3.1. Machine Learning

        16.3.2. Other Technologies

    16.4. Market Value Forecast, by Drug Type, 2017–2031

        16.4.1. Small Molecules

        16.4.2. Large Molecules

    16.5. Market Value Forecast, by Application, 2017–2031

        16.5.1. Oncology

        16.5.2. Infectious Diseases

        16.5.3. Neurological Disorders

        16.5.4. Rare Diseases

        16.5.5. Metabolic Diseases

        16.5.6. Cardiovascular Diseases

        16.5.7. Others

    16.6. Market Value Forecast, by End-user, 2017–2031

        16.6.1. Pharmaceutical & Biotechnology Companies

        16.6.2. Contract Research Organizations

        16.6.3. Academics & Research

        16.6.4. Others

    16.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Market Attractiveness Analysis

        16.8.1. By Offering

        16.8.2. By Technology

        16.8.3. By Drug Type

        16.8.4. By Application

        16.8.5. By End-user

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player - Competition Matrix (by tier and size of companies)

    17.2. Market Share Analysis/Ranking, by Company, 2020

    17.3. Company Profiles

        17.3.1. Exscientia

            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.1.2. Company Financials

            17.3.1.3. Growth Strategies

            17.3.1.4. SWOT Analysis

        17.3.2. GNS Healthcare

            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.2.2. Company Financials

            17.3.2.3. Growth Strategies

            17.3.2.4. SWOT Analysis

        17.3.3. Cloud Pharmaceuticals, Inc.

            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.3.2. Company Financials

            17.3.3.3. Growth Strategies

            17.3.3.4. SWOT Analysis

        17.3.4. Benevolent AI

            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.4.2. Company Financials

            17.3.4.3. Growth Strategies

            17.3.4.4. SWOT Analysis

        17.3.5. PathAI, Inc.

            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.5.2. Company Financials

            17.3.5.3. Growth Strategies

            17.3.5.4. SWOT Analysis

        17.3.6. Berg Health

            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.6.2. Company Financials

            17.3.6.3. Growth Strategies

            17.3.6.4. SWOT Analysis

        17.3.7. Atomwise

            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.7.2. Company Financials

            17.3.7.3. Growth Strategies

            17.3.7.4. SWOT Analysis

        17.3.8. Insitro

            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.8.2. Company Financials

            17.3.8.3. Growth Strategies

            17.3.8.4. SWOT Analysis

        17.3.9. Cyclica

            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.9.2. Company Financials

            17.3.9.3. Growth Strategies

            17.3.9.4. SWOT Analysis

        17.3.10. BlackThorn Therapeutics

            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.10.2. Company Financials

            17.3.10.3. Growth Strategies

            17.3.10.4. SWOT Analysis

        17.3.11. Insilico Medicine

            17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.11.2. Company Financials

            17.3.11.3. Growth Strategies

            17.3.11.4. SWOT Analysis

        17.3.12. Notable Labs

            17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.12.2. Company Financials

            17.3.12.3. Growth Strategies

            17.3.12.4. SWOT Analysis

        17.3.13. Standigm

            17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.13.2. Company Financials

            17.3.13.3. Growth Strategies

            17.3.13.4. SWOT Analysis

        17.3.14. Recursion Pharmaceuticals

            17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.14.2. Company Financials

            17.3.14.3. Growth Strategies

            17.3.14.4. SWOT Analysis

        17.3.15. BioSymetrics

            17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.15.2. Company Financials

            17.3.15.3. Growth Strategies

            17.3.15.4. SWOT Analysis

List of Tables

Table 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Offering, 2017–2031

Table 02: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Technology, 2017–2031

Table 03: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 04: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 05: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

Table 09: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

Table 10: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 11: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

Table 15: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

Table 16: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 17: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

Table 21: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

Table 22: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 25: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

Table 27: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

Table 28: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 29: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 31: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 32: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Offering, 2017–2031

Table 33: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Technology, 2017–2031

Table 34: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 35: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by Application, 2017–2031

Table 36: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global AI in Drug Discovery Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global AI in Drug Discovery Market Value Share, by Offering, 2020

Figure 03: Global AI in Drug Discovery Market Value Share, by Technology, 2020

Figure 04: Global AI in Drug Discovery Market Value Share, by Drug Type, 2020

Figure 05: Global AI in Drug Discovery Market Value Share, by Application, 2020

Figure 06: Global AI in Drug Discovery Market Value Share, by End-user, 2020

Figure 07: Global AI in Drug Discovery Market Value Share, by Indication, 2020

Figure 08: Global AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 09: Global AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

Figure 10: Global AI in Drug Discovery Market Value (US$ Mn), by Software, 2017–2031

Figure 11: Global AI in Drug Discovery Market Value (US$ Mn), by Services, 2017–2031

Figure 12: Global AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 13: Global AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

Figure 14: Global AI in Drug Discovery Market Value (US$ Mn), by Machine Learning, 2017–2031

Figure 15: Global AI in Drug Discovery Market Value (US$ Mn), by Other Technologies, 2017–2031

Figure 16: Global AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 17: Global AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 18: Global AI in Drug Discovery Market Value (US$ Mn), by Small Molecules, 2017–2031

Figure 19: Global AI in Drug Discovery Market Value (US$ Mn), by Large Molecules, 2017–2031

Figure 20: Global AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 21: Global AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 22: Global AI in Drug Discovery Market Value (US$ Mn), by Oncology, 2017–2031

Figure 23: Global AI in Drug Discovery Market Value (US$ Mn), by Infectious Diseases, 2017–2031

Figure 24: Global AI in Drug Discovery Market Value (US$ Mn), by Neurological Disorders, 2017–2031

Figure 25: Global AI in Drug Discovery Market Value (US$ Mn), by Rare Diseases, 2017–2031

Figure 26: Global AI in Drug Discovery Market Value (US$ Mn), by Metabolic Diseases, 2017–2031

Figure 27: Global AI in Drug Discovery Market Value (US$ Mn), by Cardiovascular Diseases, 2017–2031

Figure 28: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031

Figure 29: Global AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 30: Global AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Figure 31: Global AI in Drug Discovery Market Value (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017–2031

Figure 32: Global AI in Drug Discovery Market Value (US$ Mn), by Contract Research Organizations, 2017–2031

Figure 33: Global AI in Drug Discovery Market Value (US$ Mn), by Academics & Research, 2017–2031

Figure 34: Global AI in Drug Discovery Market Value (US$ Mn), by Others, 2017–2031

Figure 35: Global AI in Drug Discovery Market Value Share Analysis, by Region, 2020 and 2031

Figure 36: Global AI in Drug Discovery Market Attractiveness Analysis, by Region, 2021–2031

Figure 37: North America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 38: North America AI in Drug Discovery Market Value Share (%), by Country, 2020 and 2031

Figure 39: North America AI in Drug Discovery Market Attractiveness Analysis, by Country, 2021–2031

Figure 40: North America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 41: North America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

Figure 42: North America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 43: North America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

Figure 44: North America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 45: North America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 46: North America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 47: North America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 48: North America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 49: North America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Figure 50: Europe AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 51: Europe AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 52: Europe AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 53: Europe AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 54: Europe AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

Figure 55: Europe AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 56: Europe AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

Figure 57: Europe AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 58: Europe AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 59: Europe AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 60: Europe AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 61: Europe AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 62: Europe AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 64: Asia Pacific AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 65: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 66: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 67: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

Figure 68: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 69: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–203169

Figure 70: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 71: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 72: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 73: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 74: Asia Pacific AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 75: Asia Pacific AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Figure 76: Latin America AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 77: Latin America AI in Drug Discovery Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 78: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 79: Latin America AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 80: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–203180

Figure 81: Latin America AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 82: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

Figure 83: Latin America AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 84: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 85: Latin America AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 86: Latin America AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 87: Latin America AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 88: Latin America AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Figure 89: Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 90: Middle East & Africa AI in Drug Discovery Market Value Share (%), by Country/Sub-Region, 2020 and 2031

Figure 91: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 92: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Offering, 2020 and 2031

Figure 93: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Offering, 2021–2031

Figure 94: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Technology, 2020 and 2031

Figure 95: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Technology, 2021–2031

Figure 96: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Drug Type, 2020 and 2031

Figure 97: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Drug Type, 2021–2031

Figure 98: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by Application, 2020 and 2031

Figure 99: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by Application, 2021–2031

Figure 100: Middle East & Africa AI in Drug Discovery Market Value Share Analysis, by End-user, 2020 and 2031

Figure 101: Middle East & Africa AI in Drug Discovery Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

771

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved